Related Experiment Video
Updated: May 20, 2026

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
A Risk Score without a Window: The Clinical Timing Problem of Observatoire Régional Breton sur l'Infarctus Risk Score
Sarah Louise Duus Holle1, Helle Søholm2,3, Martin Frydland2,4
1Department of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, sarah.louise.duus.holle@regionh.dk.
Insights
The ORBI risk score effectively predicts in-hospital cardiogenic shock (CS) in ST-elevation myocardial infarction (STEMI) patients. However, it significantly overestimates the risk of post-procedural CS, requiring recalibration for clinical use.
Area of Science:
- Cardiology
- Clinical Risk Stratification
Background:
- Cardiogenic shock (CS) is a critical complication of ST-elevation myocardial infarction (STEMI), contributing significantly to mortality.
- The ORBI risk score was developed to estimate in-hospital CS risk using pre- and post-procedural angiographic data.
Purpose of the Study:
- To prospectively validate the ORBI risk score for predicting in-hospital CS in STEMI patients.
- To assess the ORBI score's ability to identify post-procedural CS when all components are available.
Main Methods:
- Prospective registration of consecutive adult STEMI patients without CS at admission.
- Evaluation of discrimination and calibration of the ORBI score for in-hospital and post-procedural CS.
- Analysis of 2,713 patients with median follow-up during 2022-2025.
Main Results:
- The ORBI score demonstrated strong discrimination for in-hospital CS (AUC 0.89) and post-procedural CS (AUC 0.87).
- Low-risk patients (ORBI ≤7) had a 1.0% incidence of in-hospital CS, while high-risk patients (ORBI ≥13) had a 40% incidence.
- The score substantially overestimated post-procedural CS risk in the evaluated cohort.
Conclusions:
- The ORBI risk score is a well-performing tool for predicting in-hospital CS in STEMI.
- The ORBI score requires recalibration to accurately guide post-percutaneous coronary intervention (PCI) decisions due to overestimation of post-procedural CS risk.
Introduction:
Cardiogenic shock (CS) is a main cause of mortality in ST-elevation myocardial infarction (STEMI). The ORBI risk score estimates in-hospital CS risk using pre- and post-procedural angiographic variables. The study aimed to prospectively validate the ORBI risk score for predicting in-hospital CS and to assess its ability to identify post-procedural CS, when all score components are available.
Methods:
Consecutive adult STEMI patients without CS at admission were prospectively registered at a tertiary hospital during 2022-2025. Discrimination and calibration were evaluated in all patients and among patients with post-procedural CS after leaving the catheterization laboratory.
Results:
Among 2,713 adult patients (median age 64 years; 24% female), the median ORBI score was 4 (IQR 2-7), and 103 patients (3.8%) developed in-hospital CS. Among all patients, 80% were low risk (ORBI ≤7) with 1.0% developing in-hospital CS; 13% were low-to-intermediate risk (ORBI 8-10) with 5.6% developing CS; 3.1% were intermediate-to-high risk (ORBI 11-12) with 23% developing CS; and 3.9% were high risk (ORBI ≥13), of whom 40% developed in-hospital CS. The score demonstrated strong discrimination (area under the receiver operating characteristic curve [AUC] 0.89; 95% CI: 0.87-0.94) for in-hospital CS and for post-procedural CS (AUC 0.87; 95% CI: 0.83-0.95). In patients with in-hospital CS, 68% developed peri-procedural CS. Among patients with post-procedural, CS the score substantially overestimated CS risk.
Conclusions:
The ORBI risk score performed well at predicting in-hospital CS but markedly overestimated post-procedural CS risk. As post-procedural CS is the clinically relevant endpoint for a model incorporating post-procedural variables, the ORBI score requires recalibration before it can be used to guide post-PCI decisions.
Related Concept Videos
Relative Risk
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Receiver Operating Characteristic Plot
Acute Coronary Syndrome III: Diagnostic Studies
Aneurysm II: Clinical Manifestations and Diagnostic Studies
